SCHEMBL285119

SCHEMBL285119

CCCCCCOC(C(=O)O)(C(CCCC)C(=O)O)C(CCCCCC)(CCCCCC)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSPD1 P10809 1/20 0.43
BLM P54132 1/20 0.43
HSPE1 P61604 1/20 0.43
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LCK P06239 1/20 0.37
PPARD Q03181 1/20 0.37
ZDHHC20 Q5W0Z9 1/20 0.37
ZDHHC2 Q9UIJ5 1/20 0.37
PLA2G2C Q5R387 3/20 0.36
GPR84 Q9NQS5 3/20 0.35
FFAR1 O14842 1/20 0.35
MAPT P10636 1/20 0.34
ACE2 Q9BYF1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL820028 0.97 HSPD1 (0.46) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL375645 0.97 HSPD1 (0.46) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL8746528 0.92 HSPD1 (0.46) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL9400013 0.92 HSPD1 (0.38) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL17995738 0.89 HSPD1 (0.40) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL17995590 0.87 HSPD1 (0.38) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL6663512 0.86 HSPD1 (0.37) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL7091309 0.82 HSPD1 (0.33) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL16319164 0.82 HSPD1 (0.44) HSPD1BLMHSPE1MEN1HPGD
SCHEMBL4728898 0.81 HSPD1 (0.46) HSPD1BLMHSPE1MEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2613754-B1 CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2018-10-17 EP disclosed
US-9216141-B2 Curable composition, process of production and use thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2015-12-22 US disclosed
EP-2582765-B1 2-ETHYLHEXYL METHYL TEREPHTHALATE AS PLASTICISERS IN ADHESIVES OR SEALANTS BASF SE (DE) 2014-10-15 EP disclosed
EP-2040857-B1 LIQUID DISPENSER FOR MEDICAL PURPOSES IN THE FORM OF AN APPLICATOR AESCULAP AG (DE) 2014-07-02 EP disclosed
EP-2613754-A1 CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF 3M Innovative Properties Company (US) 2013-07-17 EP disclosed
US-20130157226-A1 CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-06-20 US disclosed
EP-2588246-A1 PROCESS FOR PREPARING A THIXOTROPING AGENT AND USE THEREOF Construction Research & Technology GmbH (DE) 2013-05-08 EP disclosed
EP-2582765-A1 2-ETHYLHEXYL METHYL TEREPHTHALATE AS PLASTICISERS IN ADHESIVES OR SEALANTS BASF SE (DE) 2013-04-24 EP disclosed
WO-2012033633-A1 CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-15 WO disclosed
EP-2428199-A1 Curable composition, process of production and use thereof 3M Innovative Properties Company (US) 2012-03-14 EP disclosed
WO-2012000774-A1 PROCESS FOR PREPARING A THIXOTROPING AGENT AND USE THEREOF CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) 2012-01-05 WO disclosed
WO-2011161037-A1 2-ETHYLHEXYL METHYL TEREPHTHALATE AS PLASTICISERS IN ADHESIVES OR SEALANTS BASF SE (DE) 2011-12-29 WO disclosed
EP-2040857-A1 LIQUID DISPENSER FOR MEDICAL PURPOSES IN THE FORM OF AN APPLICATOR AND USE OF THE SAME Aesculap AG (DE) 2009-04-01 EP disclosed
WO-2008009386-A1 LIQUID DISPENSER FOR MEDICAL PURPOSES IN THE FORM OF AN APPLICATOR AND USE OF THE SAME AESCULAP AG (DE) 2008-01-24 WO disclosed
US-6726671-B2 Cell storage maintenance and monitoring system GAMBRO, INC. 2004-04-27 US disclosed
US-20020040216-A1 Cell storage maintenance and monitoring system GAMBRO, INC. 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130157226-A1 CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF LDHA, LDHB, SOD1 HSPD1 2398/4885BLM 250/4885HSPE1 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.